RET in breast cancer: functional and therapeutic implications.
about
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.mRNA expression of DOK1-6 in human breast cancerIntegrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer dataUnique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsTargeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinomaPrognostic significance of the expression of GFRα1, GFRα3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma.Downregulation of steroid receptor coactivator-2 modulates estrogen-responsive genes and stimulates proliferation of mcf-7 breast cancer cells.Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells.A role for estrogen receptor phosphorylation in the resistance to tamoxifen.GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast CancerRet inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients.Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancerTargeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.Long-range transcriptional regulation of breast cancer genes.Metabolic implication of tumor:stroma crosstalk in breast cancer.Copy number variation in archival melanoma biopsies versus benign melanocytic lesions.Distinct Temporal Regulation of RET Isoform Internalization: Roles of Clathrin and AP2.Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland.Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer.The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study.Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.
P2860
Q27853297-C87DDB5B-22F5-41D0-BED0-F96BC254A13BQ30486741-0252BD8C-B187-4315-A429-536C7C51C1EFQ33585060-D30EEDA6-D526-4AE9-8BAC-E9A1903FE0D3Q33670296-8597222E-4982-4233-83A1-B9D408B39850Q33750026-6BB058D2-0B9F-444B-BCD2-C17DD3BA374DQ33756991-8AE990CA-7D7C-42DA-915E-0C34D5071B2AQ33913901-4DB16B13-DF35-41C3-A39F-A1CD1FFA7EB3Q34282488-09B90587-534F-4C6B-AE73-90BCCD39E7B5Q34564120-F230E542-1C5A-45F6-B12F-40D5917B62F1Q34921964-6C7270E1-A236-4F8C-94D0-6FF7F6D192F7Q35200153-D4E9715B-9F17-48D9-BF91-AAE7563C875DQ35632738-43D68A98-04C8-426E-9F1E-0F2C687D97D3Q35684445-D0718B0D-98D6-4D0B-A57C-330368B7AED5Q36940404-F8ACF322-8D94-4ED1-8B9D-83ED330A77A3Q37214094-D367EF19-11B0-4B47-B77A-38BF06DDC3A8Q37236899-6183DEE3-AD7F-425B-98A4-DF98015C0A3EQ37295706-D2295456-EEDF-4124-808D-85902692FAFEQ37531200-14B5D542-A4F3-4BD0-9DE9-F2363393AA89Q37580294-7DA7CE1A-FACD-4899-AE3B-A64A64AB52AAQ37632218-265DE357-F36F-412B-B12B-750E2EF75FA6Q37690578-FC040D33-1182-4363-8FBD-AF685C79F44AQ37697034-1C693AB6-ED87-42CA-B1B5-B13E26C8F338Q37701896-6D4DBCFA-53A9-4E24-A092-BADB75866339Q38053130-72E80B48-A070-4393-98B0-0667181AEAAEQ38181405-A97DEB55-0C6C-44FE-B646-27C396A9E930Q38381518-0EEFC3E3-83BA-42BA-A09A-5D042C386CA1Q38841103-7992885B-E62B-4DCD-9229-80343A204240Q47135102-64589AEF-170F-4D3C-9137-7431E4D1209FQ50227566-BFCEB270-8D4E-4B43-9291-EC9CE2FAB8B0Q54118050-CF77D9D9-FA30-4BE3-8D3B-55ACF8FF5BEFQ54469607-4B589D98-B9EA-4D6A-A0F4-92D1EB8A65E4Q55109090-85D9C56D-87FC-4DA7-8538-DC667565FE5D
P2860
RET in breast cancer: functional and therapeutic implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RET in breast cancer: functional and therapeutic implications.
@en
RET in breast cancer: functional and therapeutic implications.
@nl
type
label
RET in breast cancer: functional and therapeutic implications.
@en
RET in breast cancer: functional and therapeutic implications.
@nl
prefLabel
RET in breast cancer: functional and therapeutic implications.
@en
RET in breast cancer: functional and therapeutic implications.
@nl
P1476
RET in breast cancer: functional and therapeutic implications.
@en
P2093
Ivan Plaza-Menacho
P304
P356
10.1016/J.MOLMED.2010.12.007
P577
2011-01-19T00:00:00Z